CASTIGLIA, Marta
 Distribuzione geografica
Continente #
NA - Nord America 4.585
EU - Europa 1.309
AS - Asia 542
SA - Sud America 82
AF - Africa 17
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.540
Nazione #
US - Stati Uniti d'America 4.574
IT - Italia 543
CN - Cina 279
DE - Germania 203
SG - Singapore 191
FI - Finlandia 124
RU - Federazione Russa 83
IE - Irlanda 79
GB - Regno Unito 74
BR - Brasile 70
BE - Belgio 43
SE - Svezia 39
UA - Ucraina 30
IN - India 23
RO - Romania 20
FR - Francia 18
CI - Costa d'Avorio 11
NL - Olanda 11
TR - Turchia 11
IR - Iran 10
CA - Canada 9
ES - Italia 9
KR - Corea 9
CH - Svizzera 7
HK - Hong Kong 7
AR - Argentina 5
AT - Austria 5
DK - Danimarca 4
EC - Ecuador 4
AU - Australia 3
CZ - Repubblica Ceca 3
PL - Polonia 3
CL - Cile 2
EU - Europa 2
JP - Giappone 2
MK - Macedonia 2
TW - Taiwan 2
AL - Albania 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
IQ - Iraq 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
MC - Monaco 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TN - Tunisia 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 6.540
Città #
Fairfield 855
Ashburn 433
Woodbridge 378
Chandler 374
Seattle 343
Wilmington 321
Cambridge 294
Houston 282
Ann Arbor 250
Singapore 158
Palermo 157
Dublin 78
Medford 77
Des Moines 70
Nanjing 54
New York 52
Altamura 51
Princeton 51
Dearborn 50
San Diego 43
Saint Petersburg 42
Brussels 41
Lawrence 39
Santa Clara 35
Boardman 30
Ludwigshafen am Rhein 28
Jinan 24
Shenyang 23
Kitzingen 22
Council Bluffs 18
Bremen 17
Beijing 15
Jiaxing 15
Phoenix 15
Rome 15
Tulsa 14
Helsinki 13
Kumar 13
Nanchang 13
Hebei 12
Munich 12
Redwood City 12
San Paolo di Civitate 12
Tianjin 12
Abidjan 11
Changsha 11
London 10
Ningbo 10
Falls Church 8
Hangzhou 8
Jacksonville 8
Hanover 7
Izmir 7
Los Angeles 7
Seongnam 7
Tehran 7
Zhengzhou 7
Aversa 6
Guangzhou 6
Milan 6
Nürnberg 6
Orange 6
Pune 6
Hong Kong 5
Nuremberg 5
São Paulo 5
Venice 5
Washington 5
Cagliari 4
Columbus 4
Kunming 4
Norwalk 4
Quito 4
Rio de Janeiro 4
Tappahannock 4
Agrigento 3
Amsterdam 3
Belo Horizonte 3
Chicago 3
Curitiba 3
Dordrecht 3
Edinburgh 3
Frankfurt am Main 3
Hengshui 3
Islington 3
Mascalucia 3
Monreale 3
Moscow 3
Naples 3
Salvador 3
Baotou 2
Barcelona 2
Bari 2
Brasília 2
Brzeg 2
Buenos Aires 2
Campinas 2
Charlottesville 2
Chengdu 2
Duezce 2
Totale 5.125
Nome #
EGFR inhibition in NSCLC: New findings…. and opened questions? 258
Dietary restriction: could it be considered as speed bump on tumor progression road? 219
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 217
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 204
E26The effects of LIPUS on ctDNA release in the medium of NSCLC cell lines 196
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 195
EFFECT OF miR-21, miR-182 AND let-7i ON TSP-1 EXPRESSION IN COLON CANCER CELL LINE 186
Liquid Biopsy in Breast Cancer 185
A headlight on liquid biopsies: a challenging tool for breast cancer management 184
Immunohistochemical/histochemical double staining method in the study of columnar metaplasia of the oesophagus 176
Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer? 174
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 173
Nintedanib in NSCLC: Evidence to date and place in therapy 170
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 166
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway 164
Spheroids from adipose-derived stem cells exhibit an miRNA profile of highly undifferentiated cells 164
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 154
Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians. 153
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? 153
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 152
Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice 151
Adipose tissue, angiogenesis and angio-MIR under physiological and pathological conditions 151
Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines 150
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 145
Exosomal miRNA analysis in non-small cell lung cancer (NSCLC) patients' plasma through qPCR: A feasible liquid biopsy tool 142
Cancer and the microbiome: Potential applications as new tumor biomarker 136
Liquid biopsies in lung cancer: The new ambrosia of researchers 134
Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC) 131
Involvement of non-coding RNAs in chemo- and radioresistance of colorectal cancer 125
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 119
Technical Aspects for the Evaluation of Circulating Nucleic Acids (CNAs): Circulating Tumor DNA (ctDNA) and Circulating MicroRNAs 106
Liquid Biopsy in Gynecological Cancers 106
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 104
Liquid Biopsy in Gastrointestinal Stromal Tumor 100
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 100
An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesistargeting TKI-based therapy 98
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes 98
CALR MUTATIONS IN SICILIAN ESSENTIAL THROMBOCYTHEMIA AND MYELOFIBROSIS PATIENTS. 94
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 92
Cell quality evaluation with gene expression analysis of spheroids (3D) and adherent (2D) adipose stem cells 91
MOLECULAR ANALYSIS OF BRCA1/2 GENES AND MULTIGENE-PANEL TESTING IN SICILIAN TRIPLE NEGATIVE BREAST CANCER 86
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 82
Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab 80
Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (Scientific Reports, (2018), 8, 1, (13379), 10.1038/s41598-018-30780-4) 80
The role of microRNAs in driving EGFR-TKI resistance in NSCLC cell lines 75
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 71
null 69
Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546] 68
Molecular analysis of Spheroids from Adipose-derived Stem Cells (S-ASCs) during in vitro long-term culture. 62
The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis 48
HEREDITARY BREAST AND OVARIAN CANCER SYNDROME: FREQUENCY AND DISTRIBUTION OF BRCA1/2 PATHOGENIC VARIANTS IN SICILIAN POPULATION 48
LIQUID BIOPSY AS A DYNAMIC TOOL FOR LUNG CANCER MANAGEMENT: A FEASIBILITY STUDY FOR PLASMA-DERIVED EXOSOMAL miRNAs AND CELL-FREE DNA. 28
null 25
Technical Aspects for the Evaluation of Circulating Tumor Cells (CTCs) 16
null 6
P2.06: Exosomal miRNA Analysis in Non-Small Cell Lung Cancer: New Liquid Biomarker?: Track: Biology and Pathogenesis 1
Totale 6.861
Categoria #
all - tutte 26.240
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.240


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020567 0 0 0 0 0 0 0 136 143 115 130 43
2020/2021981 88 23 71 76 73 76 71 76 95 149 113 70
2021/2022707 51 144 31 28 31 40 32 40 76 76 51 107
2022/20231.025 100 189 26 152 110 151 65 75 97 5 36 19
2023/2024445 17 70 27 39 23 96 55 30 3 12 5 68
2024/2025511 19 72 62 98 56 41 111 52 0 0 0 0
Totale 6.861